Format

Send to

Choose Destination
Neuro Oncol. 2019 Jun 7. pii: noz104. doi: 10.1093/neuonc/noz104. [Epub ahead of print]

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Author information

1
Dana-Farber Cancer Institute, Boston, MA, USA.
2
Harvard Medical School, Boston, MA, USA.
3
University of California, San Francisco, San Francisco, CA, USA.
4
MD Anderson Cancer Center, Houston, TX, USA.
5
Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
6
National Brain Tumor Society, Newton, MA, USA.
7
International Brain Tumour Alliance, Tadworth, Surrey, United Kingdom.
8
The Sontag Foundation and Brain Tumor Network, Ponte Vedre Beach, FL, USA.
9
The Musella Foundation for Brain Tumor Research and Information, Hewlett, NY, USA.
10
American Brain Tumor Association, Chicago, IL, USA.
11
Foundation Medicine, Cambridge, MA, USA.
12
Mayo Clinic, Rochester, MN, USA.
13
Essentia Health, Duluth, MN, USA.
14
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
15
University of Western Ontario, London, Ontario, Canada.
16
Miami Cancer Institute, Miami, FL, USA.
17
Moffitt Cancer Center, Tampa, FL, USA.
18
Accelerate Brain Cancer Cure (ABC), Washington, DC, USA.
19
Erasmus University Hospital, Rotterdam, Netherlands.
20
University Hospital and University of Zurich, Zurich, Switzerland.

Abstract

Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next five years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

PMID:
31175826
DOI:
10.1093/neuonc/noz104

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center